Glutamate Concentration in the Superior Temporal Sulcus Relates to Neuroticism in Schizophrenia by Balz, Johanna et al.
fpsyg-09-00578 May 3, 2018 Time: 17:34 # 1
ORIGINAL RESEARCH








Kanazawa Medical University, Japan
Ronald Gurrera,








This article was submitted to
Perception Science,
a section of the journal
Frontiers in Psychology
Received: 15 January 2018
Accepted: 05 April 2018
Published: 07 May 2018
Citation:
Balz J, Roa Romero Y, Keil J,
Schubert F, Ittermann B, Mekle R,
Montag C, Gallinat J and
Senkowski D (2018) Glutamate
Concentration in the Superior
Temporal Sulcus Relates
to Neuroticism in Schizophrenia.
Front. Psychol. 9:578.
doi: 10.3389/fpsyg.2018.00578
Glutamate Concentration in the
Superior Temporal Sulcus Relates to
Neuroticism in Schizophrenia
Johanna Balz1* , Yadira Roa Romero1, Julian Keil2, Florian Schubert3, Bernd Ittermann3,
Ralf Mekle4, Christiane Montag1, Jürgen Gallinat5 and Daniel Senkowski1*
1 Department of Psychiatry and Psychotherapy, St. Hedwig Hospital, Charité – Universitätsmedizin Berlin, Berlin, Germany,
2 Department of Biological Psychology, Christian-Albrechts-University Kiel, Kiel, Germany, 3 Physikalisch-Technische
Bundesanstalt, Berlin, Germany, 4 Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, Berlin, Germany,
5 Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
Clinical studies suggest aberrant neurotransmitter concentrations in the brains of
patients with schizophrenia (SCZ). Numerous studies have indicated deviant glutamate
concentrations in SCZ, although the findings are inconsistent. Moreover, alterations
in glutamate concentrations could be linked to personality traits in SCZ. Here,
we examined the relationships between personality dimensions and glutamate
concentrations in a voxel encompassing the occipital cortex (OCC) and another voxel
encompassing the left superior temporal sulcus (STS). We used proton magnetic
resonance spectroscopy to examine glutamate concentrations in the OCC and the
STS in 19 SCZ and 21 non-psychiatric healthy control (HC) participants. Personality
dimensions neuroticism, extraversion, openness, agreeableness and conscientiousness
were assessed using the NEO-FFI questionnaire. SCZ compared to HC showed
higher glutamate concentrations in the STS, reduced extraversion scores, and
enhanced neuroticism scores. No group differences were observed for the other
personality traits and for glutamate concentrations in the OCC. For the SCZ group,
glutamate concentrations in STS were negatively correlated with the neuroticism scores
[r = −0.537, p = 0.018] but this was not found in HC [r(19) = 0.011, p = 0.962].
No other significant correlations were found. Our study showed an inverse relationship
between glutamate concentrations in the STS and neuroticism scores in SCZ. Elevated
glutamate in the STS might serve as a compensatory mechanism that enables patients
with enhanced concentrations to control and prevent the expression of neuroticism.
Keywords: schizophrenia, glutamate, neuroticism, magnetic resonance spectroscopy, superior temporal sulcus
INTRODUCTION
A large proportion of people diagnosed with schizophrenia (SCZ) show a chronic progression of
positive and negative symptoms, cognitive impairments, as well as social dysfunction (Millan et al.,
2016). Aberrant neurotransmission involving the neurotransmitter glutamate likely contributes
to the development and progression of this disorder (Javitt and Zukin, 1991; Coyle, 1996).
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The glutamate hypothesis posits changes in glutamatergic
synapses and alterations in glutamatergic pathways in SCZ
(Coyle, 2006; Javitt, 2010; Kantrowitz and Javitt, 2010; Poels et al.,
2014a,b). In support of this hypothesis, various studies have
suggested a link between glutamate and psychosis (Egerton et al.,
2012; Wijtenburg et al., 2015; Treen et al., 2016).
Glutamatergic synapses are found in the entire brain.
However, alterations in glutamate-mediated neurotransmission
and glutamate concentrations in SCZ seem to be confined to
specific brain regions (Gallinat et al., 2016). To date, only
few studies with SCZ patients have examined glutamatergic
neurotransmission in the temporal lobe (Atagün et al., 2015;
Hugdahl et al., 2015). For example, Hugdahl et al. (2015)
reported decreased glutamate levels in the temporal lobe in SCZ
compared to HC. However, the authors also found increased
glutamate concentrations in a subgroup of SCZ patients with
auditory hallucinations. In addition, another study has measured
brain metabolites in the left superior temporal cortex in small
participant samples but did not find differences in glutamate
concentrations between SCZ and HC (Atagün et al., 2015). The
superior temporal cortex is crucially involved in the processing
and integration of information from multiple sensory modalities
(Maier et al., 2008; Keil and Senkowski, 2018). Moreover,
processing in the STS has an impact on perception (Balz et al.,
2016). Hence, it is possible that interindividual differences at
the synaptic and systemic levels in the superior temporal cortex
also shape personality traits (Lu et al., 2014; Ikeda et al.,
2015; Tseng et al., 2015; Li et al., 2017; Riccelli et al., 2017).
For example, one study in healthy adults revealed a positive
correlation between neuroticism scores and cortical thickness
in the STS (Riccelli et al., 2017). In addition, the study showed
negative correlations between both neuroticism and extraversion
scores with the STS surface area and cortical volume. Another
study using EEG reported an increase in functional connectivity
between the insular cortex and STS during the processing of
unpleasant emotions (Ikeda et al., 2015). Moreover, the study
revealed that neural responses to unpleasant emotional stimuli
in the inferior temporal gyrus were higher in participants with
high neuroticism compared to participants with low neuroticism
scores. Thus, differences in the STS architecture as well as
in information processing in this area seem to be related to
personality traits.
Studies investigating the Big Five personality traits in SCZ
have consistently shown enhanced neuroticism and diminished
extraversion scores (Berenbaum and Fujita, 1994; Gurrera et al.,
2000; Camisa et al., 2005; Boyette et al., 2013; Ohi et al.,
2016). Personality traits in SCZ relate to clinical symptoms,
cognitive deficits, and impaired social function (Herrán et al.,
2006; Kirihara et al., 2012; Gurrera et al., 2014; Compton et al.,
2015). In addition, personality traits affect both the onset and
the progression of SCZ (Van Os and Jones, 2001; Gleeson et al.,
2005; Lönnqvist et al., 2009). Furthermore, post-mortem studies
have indicated that glutamatergic neurobiological mechanisms
might contribute to the susceptibility to neuroticism (Hettema
et al., 2006; Ohi et al., 2017). Hence, it may be that alterations in
the glutamatergic system relate to the SCZ psychopathology, as
expressed in altered personality traits.
Thus far, no study has examined the link between glutamate
concentration and personality traits in the superior temporal
lobe. Recent magnetic resonance spectroscopy (MRS) studies
have suggested both increased and decreased glutamate
concentrations in the occipital lobe of SCZ patients (Chang et al.,
2007; Thakkar et al., 2017). However, others studies did not find
such alterations (Goto et al., 2012; Marsman et al., 2014). While
higher and lower glutamate concentrations have been frequently
reported in various brain areas of patients compared to control
participants (Marsman et al., 2013; Poels et al., 2014a; Wijtenburg
et al., 2015; Merritt et al., 2016), the functional significance of
these alterations for the SCZ pathology are not well understood.
In this study we examined glutamate concentrations in the OCC
and the left STS of SCZ and healthy control (HC) participants.
We used proton MRS to examine glutamate concentrations.
Additionally, we assessed the Big Five personality dimensions
using the NEO-FFI questionnaire (Costa and McCrae, 1992).
We computed correlations between glutamate concentrations
and those personality dimensions that differed between groups.
This was carried out separately for each voxel and group.
Since findings in the literature are relatively inconsistent, we
hesitated deriving specific hypotheses regarding alterations in
glutamate concentration in SCZ for the two obtained voxels.
For the personality traits, we expected higher neuroticism scores
and lower extraversion scores in SCZ than in HC. Finally, we
explored whether alterations in glutamate concentrations serve
as a marker for personality traits, especially neuroticism and
extraversion, in SCZ and HC.
MATERIALS AND METHODS
Participants
Twenty-three patients with the diagnosis schizophrenia
were recruited from outpatient units of the Charité –
Universitätsmedizin Berlin. The ICD-10 criteria, as used in
Germany to classify psychiatric disorders, were applied. In
addition, 23 healthy control participants matched for age,
education, gender, and handedness, were recruited for the
study. As it was not possible to recruit an equal amount
of male and female SCZ patients that fitted our inclusion
criteria, we made sure to maintain the same ratio for the
HC group. The study was conducted in accordance with the
Declaration of Helsinki and approved by the ethics committee
of the Charité – Universitätsmedizin Berlin. All participants
were additionally screened for mental disorders with the
German version of the Structural Clinical Interview for DSM-
IV-TR (SCID; First et al., 2002). This was done to assure
that there were no co-morbidities in the patient group and
no psychiatric disorders in the control group. Three SCZ
elected not to complete the MRS scan. Furthermore, MRS
data could not be obtained from one SCZ and two HC due
to scanner malfunction. These participants were excluded
from further analysis. The clinical diagnosis was assessed by a
senior psychiatrist at the recruiting institution. All participants
provided written informed consent, had normal hearing, normal
or corrected to normal vision, and no other neurological
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disorders, alcohol or substance abuse. A random sample of
40% of all participants underwent a multi-drug screening test.
Severity of symptoms in SCZ was assessed with the Positive
and Negative Syndrome Scale (PANSS; Kay et al., 1987). To test
cognitive performance, the Brief Assessment of Cognition in
Schizophrenia (BACS; Keefe et al., 2004) was administered. The
five major personality dimensions (Neuroticism; Extraversion;
Openness; Agreeableness; Conscientiousness) were assessed with
the NEO-FFI questionnaire (Costa and McCrae, 1989, 1992).
Table 1 provides an overview on demographic data, cognitive
performance, and clinical scores of the study participants.
MR Methods
MR images and spectra were collected on a 3 T Verio (Siemens
Healthcare, Erlangen, Germany). Anatomical images were
acquired using a three-dimensional T1-weighted magnetization
prepared gradient-echo sequence (MPRAGE) with an isotropic
resolution of 1.0 mm, a repetition time (TR) of 2.3 s, an echo time
TABLE 1 | Demographic data, positive and negative syndromes, and cognitive scores in the study participants.
Patients Controls Statistics
Mean SD Mean SD t-values p-values
Age (years) 36.26 8.68 36.29 8.14 −0.008 0.993
Education (years) 11.00 1.63 11.24 1.61 −0.464 0.645
Illness duration (years) 8.74 5.39 – – – –
Chlorpromazin Eq. (daily dosage/mg) 379.47 162.94 – – – –
N N
Gender (m/f) 12/7 14/7
Handedness (r/l) 16/3 18/3











Verbal Memory 40.16 11.75 49.38 10.12 −2.667 0.011
Digit Sequencing 18.63 4.07 20.95 3.98 −1.821 0.076
Token Motor 65.00 12.45 76.14 9.84 −3.156 0.003
Verbal Fluency 45.11 13.12 54.81 16.01 −2.084 0.044
Symbol coding 50.68 9.85 58.43 13.75 −2.028 0.050
Tower of London 17.32 3.15 17.81 2.36 −0.565 0.575
Total score 236.89 35.31 277.52 36.29 −3.581 0.001
PANSS
Positive 10.37 2.27 – – – –
Negative 15.53 2.52 – – – –
Disorganization 7.74 1.82 – – – –
Excited 8.37 .90 – – – –
Depressed 8.11 1.10 – – – –
NEO – FFI
Neuroticism 25.63 6.34 15.90 7.49 4.407 0.000
Extraversion 21.74 4.68 27.62 3.85 −4.358 0.000
Openness 30.37 5.84 31.43 7.30 −0.504 0.617
Agreeableness 30.95 4.43 32.29 4.64 −0.931 0.358
Conscientiousness 32.26 6.13 34.67 5.70 −1.286 0.206
The table depicts demographic data and BACS scores for SCZ and HC, as well as PANSS scores for SCZ. BACS, Brief Assessment of Cognition in Schizophrenia; PANSS,
Positive and Negative Syndrome Scale. ∗Note that most patients received more than one antipsychotic medication, and two patients received additional antidepressive
co-medication. No mood stabilizers, anticonvulsants or sedatives were prescribed.
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(TE) of 3.03 ms, an inversion time (TI) of 900 ms, and a flip angle
of 9◦. The volume of interest (VOI = 20 mm× 30 mm× 20 mm)
for single voxel MRS, encompassing the left STS, was positioned
below the upper bank of the temporal cortex (Figure 1A). The
second VOI (30 mm × 20 mm × 20 mm) was positioned
centrally, encompassing the occipital cortex (OCC) (Figure 1B).
The transmitter radiofrequency (RF) voltage was calibrated for
the individual VOI, followed by adjustment of first- and second-
order shims using FAST(EST)MAP (Gruetter and Boesch, 1992;
Gruetter and Tkac, 2000). Spin echo full intensity acquired
localized (SPECIAL) (Mlynárik et al., 2006) spectra were
acquired. The short echo time of the SPECIAL sequence enables
the determination of a large number of metabolites and yields
a high precision for the detection of glutamate (Mekle et al.,
2009; Schubert et al., 2017). The sequence was used with water
suppression by VAPOR (variable power radio frequency pulses
with optimized relaxation delays; Tkac et al., 1999), and six
outer volume suppression slices placed around the spectroscopic
voxel to saturate outside spins. For each metabolite spectrum
the number of acquisitions (NA) was 256 with TR = 3 s and
TE = 8.5 ms. Following this scan, a spectrum without water
suppression was recorded (NA = 8).
If the water line width calculated from a fit to the water
spectrum after shimming was greater than or equal to 9.5 Hz,
all corresponding MRS data were excluded from further analysis.
The mean water line width (±standard deviation) of the
remaining dataset (n = 40) was determined to be 8.5 (±1.3) Hz in
STS and 7.6 (±1.1) in OCC. Linewidth did not significantly differ
between SCZ and HC. For the analysis of the SPECIAL data, the
spectra were corrected for frequency drift during acquisition and
analyzed using LCModel (Provencher, 1993) with a simulated
basis set containing 20 metabolites.
The unsuppressed water spectrum was used for eddy current
correction and referencing the metabolite spectrum to the
internal water concentration. Cramér-Rao lower bounds of the
LCModel fits were 4.3 ± 0.7% for glutamate in the STS and
4.6 ± 1.3% for glutamate in the OCC (n = 40). Glutamate
amplitudes were corrected for relaxation using T1 and T2 values
determined at 3T (Schubert et al., 2004; Mullins et al., 2008). To
correct the in vivo concentrations for the amount of cerebrospinal
fluid (CSF) in the selected VOI, segmentation of the T1-weighted
images was performed using statistical parametric mapping
(SPM8; Litvak et al., 2011). Pixels in the VOI were classified
according to their probability calculated by SPM8 to belong to
one of the tissue types: CSF, gray matter, or white matter. The
average glutamate concentrations calculated in this manner were
8.64± 1.27 mmol/l in STS and 7.68± 1.02 mmol/l in OCC.
Data Analysis
For SCZ and HC, the NEO-FFI scores were evaluated for each
personality dimension. In a first step, we compared glutamate
concentrations in the STS and OCC between SCZ and HC. In
this comparison we used a Bonferroni-corrected alpha-level of
0.025 (0.05/2). In the next step personality dimensions between
both groups were compared using two-sample t-tests. Here,
a Bonferroni-corrected alpha-level of 0.01 (0.05/5) was used.
Significant group differences were followed up by analyses
of Pearson correlation between glutamate concentrations and
NEO-FFI scores. In this comparison we used a Bonferroni-
corrected alpha-level of 0.025 (0.05/2) within SCZ and HC. Fisher
Z-values were calculated to compare correlation coefficients
between groups. In addition, if the analysis revealed significant
correlations between glutamate concentrations and NEO-FFI
scores, we investigated whether they were mediated by the factors
age and gender in the control group and by the factors age, gender
and medication in the patients group. To statistically control
for these factors partial correlation analyses were conducted. In
patients the medication dosage was converted to chlorpromazine
equivalent (CPZE) level (Gardner et al., 2010). For exploratory
purposes, in the SCZ group, glutamate values were also related to
psychopathology scores (PANSS) using Pearson correlations.
RESULTS
SCZ showed higher glutamate concentrations in STS compared
to HC [M = 9.193, SD = 1.106 vs. M = 8.151, SD = 1.231,
t(38) = 2.806, p = 0.008; Figure 2A]. However, no significant
differences were observed for occipital glutamate concentrations
[M = 7.705, SD = 1.255 vs. M = 7.652, SD = 7.777, t(38) = 0.160,
p = 0.874]. Across groups, there were no differences in glutamate
concentrations between female and male participants [female
(n = 14): M = 21.21, SD = 8.496 vs. male (n = 26): M = 20.15,
SD = 8.582, t(38) =−0.374, p = 0.710]. The analysis of personality
traits revealed enhanced neuroticism scores [M = 25.63,
SD = 6.344 vs. M = 15.90, SD = 7.489, t(38) = 4.407, p< 0.001] and
reduced extraversion scores [M = 21.74, SD = 4.677 vs. M = 27.62,
SD = 3.853, t(38) = −4.358, p < 0.001] in SCZ compared to HC
(Figure 2B). No significant group differences were found for the
other personality traits [Openness: M = 30.37, SD = 5.842 vs.
M = 31.43, SD = 7.298, t(38) = −0.504, p = 0.617; Agreeableness:
M = 30.95, SD = 4.428 vs. M = 32.29, SD = 4.638, t(38) =−0.931,
p = 0.358; Conscientiousness: M = 32.26, SD = 6.127 vs.
M = 34.67, SD = 5.695, t(38) =−1.286, p = 0.206]. Across groups,
no significant differences in neuroticism and extraversion scores
were found between female and male participants [neuroticism:
female (n = 14): M = 21.21, SD = 8.496 vs. male (n = 26):
M = 20.15, SD = 8.582, t(38) = −0.374, p = 0.710; extraversion:
female (n = 14): M = 25.29, SD = 5.239 vs. male (n = 26):
M = 24.58, SD = 5.194, t(38) =−0.410, p = 0.684].
In the next step of the analysis, personality traits that showed
significant group differences, i.e., Extraversion and Neuroticism,
were correlated with glutamate concentrations in the STS and
OCC. This was done separately for the SCZ and HC groups.
Within the SCZ group, the glutamate concentrations correlated
negatively with the neuroticism scores [r(17) =−0.537, p = 0.018]
(Figure 3A). Higher glutamate concentrations were related to
lower neuroticism scores. However, no such correlation was
found in HC [r(19) = 0.011, p = 0.962]. Importantly, the
correlation coefficients for the relationships between neuroticism
scores and glutamate concentrations in the STS differed
significantly between groups [Fisher Z = −1.714, p = 0.043].
Next, we conducted a partial correlation analysis with the
control variables age, gender and medication, i.e., CPZE level,
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FIGURE 1 | Sample MRS spectra from the left STS voxel (A) and the OCC voxel (B). The upper panels illustrate the location of the voxel on T1-weighted images.
The top row of each panel represents the original SPECIAL spectrum. Also shown are the overall fits and the fitted components of interest. The small residuals reflect
the high quality of the fits.
FIGURE 2 | T-tests between SCZ and HC for (A) glutamate in the OCC and glutamate in the STS, and for (B) the NEO-FFI dimensions neuroticism and
extraversion. (A) The barplots show OCC and STS mean glutamate concentrations in SCZ and HC. Glutamate concentrations in the STS are elevated in SCZ
compared to HC, whereas OCC glutamate concentrations do not show any differences. (B) The barplots show differences between SCZ and HC in the personality
dimensions neuroticism and extraversion, measured by the NEO-FFI.
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FIGURE 3 | Pearson correlations for SCZ between glutamate (STS) and neuroticism, and between glutamate (STS) and extraversion. (A) In SCZ glutamate
concentrations in the STS are negatively correlated with neuroticism (n = 19). (B) In SCZ glutamate concentrations in the STS do not show any correlations with the
NEO-FFI extraversion score (n = 19).
between glutamate concentration in the STS and neuroticism
scores in SCZ. The analysis revealed a significant relationship
[r(14) = −0.518, p = 0.040], demonstrating that age, gender, and
medication did not substantially mediate the negative correlation
between glutamate concentration in the STS and neuroticism
scores in SCZ.
Further analyses revealed that for both groups, there were
no significant correlations between glutamate concentrations in
the STS and extraversion scores [SCZ: r(17) = 0.253, p = 0.295
(Figure 3B); HC: r(19) = 0.394, p = 0.077]. In addition, the
correlation analysis between glutamate concentrations in the
occipital lobe and neuroticism scores [SCZ: r(17) = −0.412,
p = 0.079; HC: r(19) = 0.136, p = 0.557], as well as
between glutamate concentration in the occipital lobe and
extraversion scores [SCZ: r(17) = −0.014, p = 0.954; HC:
r(19) = −0.102, p = 0.659], did not reveal any significant
relationships.
No relationship between glutamate and schizophrenia
symptoms, as obtained through the PANSS, was found (for all
scales p > 0.05). Moreover, there was no relationship between
glutamate concentration and cognitive capacity, measured by the
BACS (for all scales p > 0.05).
DISCUSSION
In this study we examined glutamate concentrations in the
STS and OCC in SCZ and HC. We observed that glutamate
concentrations in the STS were significantly higher for SCZ
than HC, while there were no group differences in glutamate
concentrations in the OCC. Additionally, we obtained measures
of the Big Five personality traits. In line with previous research,
we found increased neuroticism scores and reduced extraversion
scores in SCZ compared to HC. Interestingly, within SCZ
glutamate levels in the STS correlated negatively with neuroticism
scores.
Patients Exhibit Higher STS Glutamate
Concentrations Than Healthy Controls
SCZ compared to HC showed higher glutamate concentrations
in the STS, which is a key association area in the human
brain. However, we did not find group differences in glutamate
concentrations in the visual cortex. The lack of glutamate
concentration differences between SCZ and HC in the visual
cortex corresponds with a study by Marsman et al. (2014),
who examined glutamate concentrations in the parieto-occipital
cortex using a 7 T MRI scanner. The study revealed no significant
group differences in glutamate concentrations in the parieto-
occipital cortex. Previous studies measuring glutamate showed
inconsistent results: Depending on the selected brain area, some
studies did not find glutamatergic aberrations in SCZ (Marsman
et al., 2013; Poels et al., 2014a,b; Wijtenburg et al., 2015;
Merritt et al., 2016), while others did find both increased and
decreased glutamate concentrations in SCZ (Marsman et al.,
2013; Poels et al., 2014a,b; Wijtenburg et al., 2015; Merritt
et al., 2016). In the STS, however, clear results have been
missing so far. To our knowledge, only one previous study
has examined glutamate concentrations in SCZ in the left STS
in a small study sample (Atagün et al., 2015). The study did
not reveal significant differences in glutamate concentrations
between groups, perhaps due to a lack of statistical power. The
results of the current study show, for the first time, increased
glutamate concentrations in the left STS in SCZ compared
to HC.
Recent research indicates that alterations in glutamatergic
neurotransmission in SCZ do not start during the course of the
disorder but are already prevalent before the visible manifestation
Frontiers in Psychology | www.frontiersin.org 6 May 2018 | Volume 9 | Article 578
fpsyg-09-00578 May 3, 2018 Time: 17:34 # 7
Balz et al. Glutamate and Neuroticism in Schizophrenia
of symptoms (Millan et al., 2016). For example, Egerton et al.
(2012) suggested that genetic and environmental risk factors
for psychosis can interact with glutamatergic neurotransmission
and can consequently lead to the onset of SCZ. Furthermore,
several studies have suggested that individuals at high-risk for
developing a psychotic disorder show alterations in glutamate
concentrations with lower glutamate concentrations in thalamic
and higher glutamate concentration in medial frontal regions
prior to the onset of SCZ (Tibbo et al., 2004; Stone et al., 2009;
Fusar-Poli et al., 2011; Wijtenburg et al., 2015).
Generally, glutamate levels, e.g., as measured in thalamic
regions and the anterior cingulate cortex, seem to be elevated
in early stages of the psychosis as well as unmedicated first
episode SCZ patients (Théberge et al., 2002; Egerton et al., 2012;
Marsman et al., 2013; Wijtenburg et al., 2015). In contrast, the
results in chronic, medicated patients are less clear (Egerton
and Stone, 2012; Marsman et al., 2013; Poels et al., 2014a,b;
Wijtenburg et al., 2015). Some studies have suggested that
glutamate concentrations in various regions increase with age,
or medication intake (Wijtenburg et al., 2015). However, in the
present study we did not find an influence of age, or medication
on glutamate concentrations in the left STS. The meta-analysis by
Merritt et al. (2016) could also not confirm a relationship between
glutamate concentration and age, antipsychotic treatment or
symptom severity. Hence, our results suggest that glutamate
concentrations do not seem to be directly related to those factors.
Moreover, our study provides evidence that elevated glutamate
concentrations in the STS are prevalent in SCZ even in medicated
chronic patients.
Patients Rate Themselves Higher in
Neuroticism and Lower in Extraversion
Than Healthy Controls
In line with our hypothesis, SCZ patients had higher neuroticism
values and lower extraversion values than HC. Thus, our findings
are in line with previous studies about personality trait differences
in SCZ (Berenbaum and Fujita, 1994; Gurrera et al., 2000;
Camisa et al., 2005; Boyette et al., 2013; Ohi et al., 2016).
A number of studies have suggested that personality differences
between SCZ and healthy individuals are present even before the
onset of psychotic symptoms (Keshavan et al., 2005; Fryers and
Brugha, 2013; Ohi et al., 2016). Furthermore, high neuroticism
scores and low extraversion scores have been associated with
an increased risk of developing SCZ (Van Os and Jones, 2001;
Krabbendam et al., 2002; Goodwin et al., 2003; Gleeson et al.,
2005; Krug et al., 2008; Lönnqvist et al., 2009; Boyette et al.,
2013, 2015; Ohi et al., 2016). High neuroticism trait scores may
reflect a vulnerability to distress, which could contribute to the
development of SCZ (Nuechterlein et al., 1994; Boyette et al.,
2013). Recently, Ridgewell et al. (2017) discovered a relationship
between neuroticism and quality of life in SCZ. If neuroticism
is constantly higher in individuals who are at high risk for
developing SCZ, and if elevated neuroticism scores shape general
health and the onset of SCZ, then elevated neuroticism trait
scores could be a predictive marker for individuals who are
at risk of developing SCZ or progressing to a psychotic phase.
Future research should examine the predictive value of enhanced
neuroticism scores for the development of SCZ.
Neuroticism and extraversion might be a manifestation of
short-term symptoms that occur in SCZ. To test this assumption,
Boyette et al. (2015) investigated the 3-year stability of the
Big Five personality traits and found that transient psychotic
symptoms and psychotic relapse did not substantially affect
personality traits in patients with psychotic disorders. In addition,
Kentros et al. (1997) failed to show a relationship between
positive symptoms and personality trait scores in SCZ, although
a slight influence of negative symptoms on personality traits was
observed. Thus, these studies suggest that short-term symptoms
in SCZ have a relatively modest impact on personality traits in
SCZ.
When investigating personality traits in SCZ, one might argue
that patients are unable to provide a reliable self-assessment on
their personality. However, some studies have addressed this
issue and found that SCZ patients have the same ability to
rate their own personality as compared with healthy individuals
(Bell et al., 2007). Bell et al. (2007) investigated the validity
of self-report questionnaires for SCZ patients and found that
standardized personality questionnaires, such as the NEO-FFI are
valid even for patients with poor insight. Furthermore, Suslow
et al. (2014) found that not only the explicit but also the implicit
self-representation in SCZ is different from HC in the direction
of higher neuroticism and lower extraversion in SCZ. Hence,
we conclude that the personality traits measured in the current
study provide a reliable measure of the Big Five personality
dimensions in both study groups. Personality trait scores are
relatively stable over time and do not seem to be related to
the severity of the illness or to the current symptomatology of
acute psychosis symptoms. Therefore, we argue that obtained
alterations in personality trait scores, i.e., elevated neuroticism
and diminished extraversion in SCZ reflect a trait rather than a
state effect (Kentros et al., 1997; Gurrera et al., 2000; Beauchamp
et al., 2006, 2011; Boyette et al., 2015).
A Negative Correlation Between STS
Glutamate Concentrations and
Neuroticism Can Be Found in
Schizophrenic Patients
In SCZ neuroticism scores, but not extraversion scores, correlated
negatively with STS glutamate concentrations. The higher the
STS glutamate concentration in SCZ, the lower the neuroticism
scores were. Interestingly, glutamate concentrations in the STS
were linked to neuroticism in SCZ, but not in HC. HC did
not show significant correlations between STS glutamate and
neuroticism or extraversion.
So far, only a few studies have discovered negative correlations
between glutamate concentrations and symptoms of psychiatric
disorders in SCZ. For example, Egerton et al. (2014), who
examined individuals with ultra high risk of psychosis, found a
negative relationship between thalamic glutamate concentration
and the severity of positive symptoms – particularly the
severity of abnormal thought content and the severity of
perceptual abnormalities. Furthermore, longitudinal data in that
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study revealed a correlation between lower thalamic glutamate
concentrations and successive worsening of symptoms over time.
However, our study did not reveal any correlations of glutamate
with PANSS or BACS ratings, which indicates that acute
psychopathology is independent from glutamate concentration
levels in the STS and the OCC. Notably, other studies also
reported a lack of any significant relationship between acute
psychotic symptoms and glutamate concentrations, e.g., in the
anterior cingulate cortex or dorsolateral prefrontal cortex (Chiu
et al., 2017; C´urcˇic´-Blake et al., 2017).
The observed effects in the current study were relatively
weak and therefore require replication with a larger sample.
Moreover, it is not clear if an enhancement in glutamate
concentrations actually contributes to enhanced neural activity
of glutamatergic neurons. Nevertheless, we could speculate that
higher STS glutamate concentrations might be a compensatory
mechanism that protects individuals with SCZ from otherwise
higher neuroticism traits. Studies suggested that high neuroticism
scores might have a negative impact on functioning and
quality of life (Ridgewell et al., 2017). An elevated glutamate
concentration in the STS in SCZ might therefore compensate
the otherwise distinct personality differences and lead to better
overall functioning. However, this assumption requires further
testing.
Glutamate is the primary excitatory neurotransmitter
in the human brain, hence, constantly elevated glutamate
concentrations could lead to structural abnormalities and
dangerous neurotoxic effects in the SCZ brain (Marsman et al.,
2013; Plitman et al., 2016). Long-term studies are necessary
to monitor changes in glutamatergic neurotransmission over
time in SCZ and to check for damages caused by glutamatergic
aberrations. If SCZ is linked to aberrant glutamatergic
neurotransmission, then medication that can affect glutamatergic
neurotransmission may be a promising psychopharmacological
intervention target. The observation that glutamate is linked to
and affects personality could be used as a treatment option to
reduce symptoms of psychotic and other psychiatric disorders
(Carlsson, 2001; Rosenberg et al., 2004; Hoerst et al., 2010; Neill
and Frodl, 2012). However, since SCZ is a very heterogeneous
disorder, it is possible that different types of treatment will
be necessary to help to diminish the diverse symptoms in
this patient group (Chavez-Noriega et al., 2002; Howes and
Kapur, 2014; Poels et al., 2014b; Beck et al., 2016). Promising
results supporting this therapeutic avenue propose that SCZ
who do not respond to dopaminergic medication reveal normal
dopaminergic levels, but altered glutamate levels (Demjaha et al.,
2014). Consequently, drugs that target the glutamatergic system
could help in individuals who do not respond to standard
medication in SCZ, which mostly targets the dopaminergic
system.
CONCLUSION
Our study revealed that glutamate concentration in the
STS and neuroticism in SCZ are linked. Patients with SCZ
who exhibit higher glutamate concentrations in the STS
show lower neuroticism and vice versa. We propose that
glutamate could serve as a compensatory mechanism in the
SCZ brain. Specifically, enhanced glutamate concentrations
in the association cortex might enable patients to control
and subsequently prevent the expression of neuroticism.
Considering that modulations in neurotransmission also
affect personality in SCZ, monitoring and moderating the
glutamatergic concentration might help to better understand SCZ
psychopathology. Consequently, addressing the glutamatergic
dysfunction might help individuals with schizophrenia to
overcome some of the limitations resulting from their higher
neuroticism trait scores.
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